The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Open accessAbstract
BACKGROUND: Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas. METHODS: In this single-group, open-label, phase 2 study, 125 patients with indolent non-Hodgkin's lymphomas who had not had a response to rituximab and an alkylating agent or had had a relapse within 6 months after receipt of those therapies were administered idelalisib, 150 mg twice daily, until the disease progressed or the patient withdrew from the study. The primary end point was the overall rate of response; secondary end points included the duration of response, progression-free survival, and safety. RESULTS: The median age of the patients was 64 years (range, 33 to 87); patients had received a median of four prior therapies (range, 2 to 12). Subtypes of indolent non-Hodgkin's lymphoma included follicular lymphoma (72 patients), small lymphocytic lymphoma (28), marginal-zone lymphoma (15), and lymphoplasmacytic lymphoma with or without Waldenström's macroglobulinemia (10). The response rate was 57% (71 of 125 patients), with 6% meeting the criteria for a complete response. The median time to a response was 1.9 months, the median duration of response was 12.5 months, and the median progression-free survival was 11 months. Similar response rates were observed across all subtypes of indolent non-Hodgkin's lymphoma, though the numbers were small for some categories. The most common adverse events of grade 3 or higher were neutropenia (in 27% of the patients), elevations in aminotransferase levels (in 13%), diarrhea (in 13%), and pneumonia (in 7%). CONCLUSIONS: In this single-group study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment. (Funded by Gilead Sciences and others; ClinicalTrials.gov number, NCT01282424.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
Karnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
PI3K signalling: the path to discovery and understanding
Vanhaesebroeck, B., Stephens, L., & Hawkins, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3290 · Cited by 987
Friedberg, J. W., Sharman, J., Sweetenham, J., Johnston, P. B., Vose, J. M., LaCasce, A., Schaefer-Cutillo, J., De Vos, S., Sinha, R., Leonard, J. P., et al. (2010) · Blood · doi:10.1182/blood-2009-08-236471 · Cited by 747
Self-citationLannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M. M., Deininger, M., et al. (2011) · Blood · doi:10.1182/blood-2010-03-275305 · Cited by 720
Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.017 · Cited by 651
Self-citationShankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Self-citationNatural history of and therapy for the indolent non-Hodgkin's lymphomas.
Horning, S. (1993) · PubMed · Cited by 399
Bendamustine: Rebirth of an Old Drug
Cheson, B. D., & Rummel, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7252 · Cited by 266
Witzig, T. E., Wiernik, P. H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1169 · Cited by 260
Horning, S. J., Younes, A., Jain, V., Kroll, S., Lucas, J., Podoloff, D., & Goris, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.040 · Cited by 258
Kahl, B. S., Bartlett, N. L., Leonard, J. P., Chen, L., Ganjoo, K., Williams, M. E., Czuczman, M. S., Robinson, K. S., Joyce, R., van der Jagt, R. H., et al. (2010) · Cancer · doi:10.1002/cncr.24714 · Cited by 245
Self-citationBilancio, A., Okkenhaug, K., Camps, M., Emery, J. L., Ruckle, T., Rommel, C., & Vanhaesebroeck, B. (2006) · Blood · doi:10.1182/blood-2005-07-3041 · Cited by 212
Durand, C., Hartvigsen, K., Fogelstrand, L., Kim, S., Iritani, S., Vanhaesebroeck, B., Witztum, J. L., Puri, K. D., & Gold, M. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900432 · Cited by 127
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
Bella, N. D., Taetle, R., Kolibaba, K. S., Boyd, T. E., Raju, R. N., Barrera, D., Cochran, E. W., Dien, P. Y., Lyons, R. M., Schlegel, P. J., et al. (2009) · Blood · doi:10.1182/blood-2009-08-233155 · Cited by 76
Radioimmunotherapy for B-Cell Non-Hodgkin Lymphomas
Tomblyn, M. B. (2012) · Cancer Control · doi:10.1177/107327481201900304 · Cited by 61
Management of indolent lymphoma: Where are we now and where are we going
Lunning, M. A., & Vose, J. M. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.09.004 · Cited by 49
Ibritumomab tiuxetan for non-Hodgkin’s lymphoma
Johnston, P. B., Bondly, C., & Micallef, I. N. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.6.861 · Cited by 24
William, B. M., & Bierman, P. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.504707 · Cited by 16
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807315 · Cited by 1,126
Self-citation
Metadata
- Authors
- Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., Blum, K. A., Goy, A. H., Davies, A. J., Zinzani, P. L., Dreyling, M., Johnson, D., Miller, L. L., Holes, L., Li, D., Dansey, R. D., Godfrey, W. R., & Salles, G. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-03-13
- Volume
- 370
- Issue
- 11
- Pages
- 1008-1018
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134861285
- Cited by
- 1,069
- References
- 26
- FWCI
- 93.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.